Activity

Filter

Cancel
Date Panel Item Activity
5 actions
Ciliopathies v1.68 IFT57 Krithika Murali Classified gene: IFT57 as Amber List (moderate evidence)
Ciliopathies v1.68 IFT57 Krithika Murali Gene: ift57 has been classified as Amber List (Moderate Evidence).
Ciliopathies v1.67 IFT57 Krithika Murali Marked gene: IFT57 as ready
Ciliopathies v1.67 IFT57 Krithika Murali Gene: ift57 has been classified as Red List (Low Evidence).
Ciliopathies v1.67 IFT57 Krithika Murali gene: IFT57 was added
gene: IFT57 was added to Ciliopathies. Sources: Literature
Mode of inheritance for gene: IFT57 was set to BIALLELIC, autosomal or pseudoautosomal
Publications for gene: IFT57 were set to PMID:40273360
Phenotypes for gene: IFT57 were set to Bardet-Bield syndrome; ciliopathy - MONDO:0005308
Review for gene: IFT57 was set to AMBER
Added comment: PMID:40273360 Nitoiu et al 2025 report a male with clinical features of Bardet-Biedl syndrome. Phenotypic features include:
- Vision issues - night vision loss, progressive cone-rod dystrophy leading to legal blindness
- Post-axial polydactyly
- Obesity and type 2 diabetes
- Learning difficulties
- Moderate sensorineural hearing loss

Biallelic IFT57 variants were identified on short-read genomic sequencing after negative panel-based clinical testing - NM_018010.4 (IFT57): c.1190 T>A;p.(Val397Glu) and c.675del; p.(Lys225Asnfsāˆ—17).

Patient-derived fibroblasts had fewer primary cilia, abnormal ciliary morphology and abnormal anterograde transport in the primary cilia. IFT57 knockout mouse models did not form primary cilia. Treatment with IFT57-WT restored cilia formation while IFT57-Val397Glu only partially rescued cilia formation in Ift57-KO-mouse cells.
Sources: Literature